Groupama Asset Managment Has $276.73 Million Holdings in Insulet Corporation $PODD

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Groupama Asset Managment raised its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 0.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,053,759 shares of the medical instruments supplier's stock after buying an additional 3,759 shares during the quarter. Insulet comprises approximately 2.2% of Groupama Asset Managment's portfolio, making the stock its 10th biggest position. Groupama Asset Managment owned 1.50% of Insulet worth $276,728,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Larson Financial Group LLC raised its position in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT purchased a new position in Insulet in the 1st quarter worth about $26,000. SouthState Corp raised its position in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 76 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new position in Insulet in the 4th quarter worth about $42,000. Finally, Ramirez Asset Management Inc. purchased a new position in Insulet in the 1st quarter worth about $53,000.

Insulet Stock Performance

Insulet stock traded up $2.92 during midday trading on Friday, hitting $330.77. The stock had a trading volume of 499,504 shares, compared to its average volume of 705,185. The firm's fifty day moving average is $300.94 and its two-hundred day moving average is $285.90. The company has a market capitalization of $23.28 billion, a PE ratio of 100.54, a P/E/G ratio of 2.75 and a beta of 1.35. Insulet Corporation has a 52-week low of $180.31 and a 52-week high of $334.18. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm's quarterly revenue was up 32.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on PODD shares. Canaccord Genuity Group boosted their target price on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Truist Financial started coverage on Insulet in a research report on Monday, June 16th. They issued a "buy" rating and a $365.00 target price for the company. Oppenheimer boosted their target price on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Barclays boosted their target price on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research report on Thursday. Finally, Wells Fargo & Company upped their price target on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $332.71.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.